GlassScriptPhysician profile
Ximei Wang
NPI 1710316401
$1,156.26
in general payments reported to CMS, 2019-2025
20 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.01 · 2022: $223 · 2023: $91.03 · 2024: $85.08 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $161.14 | 2021-2025 | |
| Pfizer INC. | $141.53 | 2025 | |
| Gilead Sciences, INC. | $140.71 | 2024-2025 | Trodelvy |
| Lilly USA, LLC | $125.93 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $113.03 | 2022 | |
| Merck Sharp & Dohme LLC | $78.99 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $71.36 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $64.70 | 2023-2025 | |
| Daiichi Sankyo INC. | $41.51 | 2024 | Enhertu |
| Tersera Therapeutics LLC | $38.68 | 2025 | Zoladex |
| Abbvie INC. | $26.46 | 2025 | |
| Taiho Oncology, INC. | $23.63 | 2025 | |
| Glaxosmithkline, LLC. | $19.05 | 2025 | Ojjaara |
| Fresenius Kabi USA, LLC | $18.29 | 2025 | |
| Amgen INC. | $16.92 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $16.33 | 2025 | Onivyde |
| Kyowa Kirin, INC. | $15.80 | 2021 | |
| Immunogen, INC. | $14.53 | 2023 | Elahere |
| E.R. Squibb & Sons, L.L.C. | $13.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2025 | Fruzaqla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ximei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.